08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia completed its acquisition of fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for $3.1 billion, including $1.4 billion in debt. The acquisition consists of L800 million ($1.2 billion) in cash, $47.5...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Amdipharm Mercury, Concordia Healthcare deal

Concordia will acquire fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for up to $3.6 billion, including debt. The acquisition consists of L800 million ($1.2 billion) in cash and 8.5 million of...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Financial News

Concordia Healthcare completes follow-on

Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX), Oakville, Ontario   Business: Neurology, Inflammation, Cancer   Date completed: 2015-09-24   Type: Follow-on   Raised: $520 million   Shares: 8 million   Price: $65   Shares after offering: 42.3...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Lansen Pharmaceutical, Novartis deal

Lansen acquired Chinese rights to the Sicorten Plus brand from Novartis for $8 million up front. Lansen said it also acquired the Swiss Marketing Authorization, know-how, books and records, specified trademarks and commercial and medical...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Amdipharm plc, Cinven Ltd., Mercury Pharma Group Ltd. deal

In October, Cinven acquired fellow generics company Amdipharm for £367 million ($582.9 million). In September, Cinven acquired U.K.-focused generics company Mercury. Cinven said Mercury had an enterprise value of £465 million ($737.7 million). Cinven said...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Company News

Amdipharm International Ltd., Invida sales and marketing update

Amdipharm granted Invida exclusive rights in eight Asian territories to commercialize nine branded generics, including Neomercazole carbimazole for hyperthyroidism. Invida is responsible for obtaining regulatory approval, if necessary, in the territories, which include Thailand, Malaysia,...
07:00 , Jul 20, 2009 |  BC Week In Review  |  Company News

Amdipharm plc, Recordati sales and marketing update

Amdipharm granted Recordati exclusive rights to market TransAct local action transcutaneous (LAT) in Italy and Portugal for symptomatic relief of localized pain involving the musculoskeletal system. The transdermal patch containing 40 mg flurbiprofen had sales...